We observed a marked difference in tumor incidence in the immunocompetent mice compared with that in the control group, in which anti-TNFR2 antibody pretreatment resulted in a lower incidence and longer tumor occurrence time; however, this difference was not observed in nude mice (figure 2A,B). The gene discussed is TNFRSF1B; the disease is neoplasm.